



Research Article

Title: Retinal thickness predicts the risk of cognitive decline in Parkinson's disease

Authors: Ane Murueta-Goyena, PhD^{1,2}, Rocío Del Pino, PhD^{1,3}, Marta Galdós, PhD⁴, Begoña Arana, PhD⁴, Marian Acera, MSc¹, Mar Carmona-Abellán, MD, PhD¹, Tamara Fernández-Valle, MD^{1,5,6}, Beatriz Tijero, MD, PhD^{1,5}, Olaia Lucas-Jiménez, PhD⁷, Natalia Ojeda, PhD⁷, Naroa Ibarretxe-Bilbao, PhD⁷, Javier Peña, PhD⁷, Jesus Cortes PhD^{8,9}, Unai Ayala¹⁰, Maitane Barrenechea¹⁰, Juan Carlos Gómez-Esteban, MD, PhD^{1,5,6}, Iñigo Gabilondo, MD, PhD^{1,5,9}

¹Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain; ²Department of Physiology, University of the Basque Country (UPV/EHU); ³International University of La Rioja, La Rioja, Spain; ⁴Ophthalmology Department, Cruces University Hospital, Barakaldo, Bizkaia, Spain; ⁵Neurology Department, Cruces University Hospital, Barakaldo, Bizkaia, Spain; ⁶Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain; ⁷Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain; ⁸Computational Neuroimaging Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain; ⁹Ikerbasque: The Basque Foundation for Science, Bilbao, Spain; ¹⁰ Mondragon Unibertsitatea, Biomedical Engineering Department, Faculty of Engineering, Mondragon, Gipuzkoa, Spain.

Corresponding author: Ane Murueta-Goyena

Corresponding author's address: Biocruces Bizkaia Health Research Institute, Plaza de Cruces 12, Barakaldo (Bizkaia), CP 48903, Spain

Corresponding author's phone and fax: +34 946006000 ext. 7961

Corresponding author's e-mail address: ANE.MURUETAGOYENA@osakidetza.eus

Running head: Retinal thinning and the risk of cognitive decline in LBD

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.25944

Acknowledgement statement (including conflict of interest and funding sources): This study was partially co-funded by Michael J. Fox Foundation [RRIA 2014 (Rapid Response Innovation Awards) Program (Grant ID: 10189)], by the Instituto de Salud Carlos III through the projects “PI14/00679” and “PI16/00005”, the Juan Rodes grant “JR15/00008” (IG) (Co-funded by European Regional Development Fund/European Social Fund - "Investing in your future"), and by the Department of Health of the Basque Government through the project “2016111009” and “2020333033”..

Keywords: neurodegeneration; visual dysfunction; optical coherence tomography

ABSTRACT

Objective: To analyze longitudinal changes of retinal thickness and their predictive value as biomarkers of disease progression in idiopathic Parkinson's disease (iPD).

Methods: Patients with Lewy body diseases (LBDs) were enrolled and prospectively evaluated at 3 years, including patients with iPD (n=42), dementia with Lewy bodies (DLB, n=4), E46K-SNCA mutation carriers (n=4) and controls (n=17). All participants underwent Spectralis retinal optical coherence tomography and Montreal Cognitive Assessment (MoCA), and Unified Parkinson's Disease Rating Scale (UPDRS) score was obtained in patients. Macular ganglion-inner plexiform layer complex (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thickness reduction rates were estimated with linear mixed models. Risk ratios were calculated to evaluate the association between baseline GCIPL and pRNFL thickness and the risk of subsequent cognitive and motor worsening, using clinically meaningful cut-offs.

Results: GCIPL thickness in the parafoveal region (1- to 3-mm ring) presented the largest reduction rate. The annualized atrophy rate was 0.63 μm in iPD patients and 0.23 μm in controls ($p < 0.0001$). iPD patients with lower parafoveal GCIPL and pRNFL thickness at baseline presented an increased risk of cognitive decline at 3 years (RR 3.49, 95% CI 1.10 – 11.1, $p = 0.03$ and RR 3.28, 95% CI 1.03 – 10.45, $p = 0.045$, respectively). We did not identify significant associations between retinal thickness and motor deterioration.

Interpretation: Our results provide evidence of the potential use of OCT-measured parafoveal GCIPL thickness to monitor neurodegeneration and to predict the risk of cognitive worsening over time in iPD.

INTRODUCTION

Cognitive impairment is a common and highly disabling feature of Parkinson's disease (PD). At diagnosis, mild cognitive impairment can be detected in 15 to 40% of PD patients and ten years after disease onset dementia affects up to 70% of patients¹⁻⁴. Some patients with aggressive phenotypes might suffer a more rapid cognitive deterioration and earlier instauration of dementia, but the lack of validated clinical biomarkers has diffculted the prediction of cognitive deterioration and the development of potential neuroprotective agents^{1, 2}. Such severe PD subtypes are believed to share clinical and pathologic commonalities with two other less common diffuse Lewy body diseases (LBD): dementia with Lewy bodies (DLB) and PD associated to E46K mutation in the α -synuclein gene (E46K-SNCA)³. Both entities are characterized by a rapidly progressive clinical deterioration with a marked cognitive impairment that precedes or coincides with the onset of parkinsonian motor signs^{4, 5}. PD patients demonstrate frequent abnormalities in visual functions, including low contrast visual acuity, contrast sensitivity, color and pattern discrimination, depth and movement perception and several higher order visuospatial abilities⁶⁻¹⁶. Interestingly, visuospatial impairment, one of the earliest and most prominent clinical features of DLB and E46K-SNCA patients, is a main predictor of global cognitive decline in PD patients¹⁷. Moreover, recent evidence support that visual tests might predict PD dementia^{18, 19}.

In line with this, the atrophy of macular ganglion cell-inner plexiform layer complex (GCIPL) measured with optical coherence tomography (OCT) has been shown to be a good marker of visual dysfunction in PD²⁰, but the link between macular GCIPL thinning and overall cognitive impairment is poorly understood. Retinal neurodegeneration, neuronal loss and anomalous α -synuclein deposits within inner retinal layers are now well-known pathological features of LBD patients²¹. Several cross-sectional studies using OCT have demonstrated that, compared to age-matched controls, PD patients have an atrophy of inner retina which seems to be associated with disease duration and motor disability²². More recent publications have shown that the thinning of macular GCIPL in PD is linked to cognitive impairment in *de novo* patients²³ and to the risk of dementia¹⁸. Interestingly, our group found that visual dysfunction in PD is selectively associated with the thinning of GCIPL in the 1- to 3-mm diameter ring area around the fovea (parafoveal

GCIPL)²⁰, an OCT feature that has been also identified in patients with idiopathic REM sleep behavior disorder - the earliest (prodromal) phases of LBD²⁴. So far, only few OCT studies have prospectively evaluated the progression of retinal thinning in PD patients²⁵⁻²⁷, but none have specifically looked at the rate of macular GCIPL atrophy and its relationship with disease worsening.

In this study, we aimed to evaluate longitudinally the dynamics of retinal atrophy and visual deterioration in PD and the ability of single-timepoint OCT measures and visual test to predict the risk of motor and cognitive decline. Furthermore, as a strategy to identify PD patients with worse prognosis, we jointly evaluated PD patients together with a cohort of controls, DLB and E46K-SNCA carriers.

METHODS

Study Design and Participants

We enrolled 62 patients with LBDs in a 3-year prospective longitudinal study, including patients with idiopathic PD (iPD, n=50), DLB patients (n=8) and E46K-SNCA carriers (n=4), and 29 controls. A total of 50 LBD patients (n=42 iPD, n=4 DLB, n=4 E46K-SNCA) and 17 controls successfully completed year 3 of follow-up assessments. Twelve patients (19%) and 12 controls (41%) were lost to follow-up: 4 DLB and 2 iPD for severe motor and cognitive worsening related to LBD, 2 iPD had hemorrhagic stroke, 1 iPD died of pneumonia, 2 iPD developed ophthalmological exclusion conditions, and 1 iPD and 12 controls missed scheduled appointments by 12 months or more. Study participants consisted in a selected cohort of patients and controls recruited between 2015 and 2018 in the Department of Neurology at Cruces University Hospital and in the Biscay PD Association. Patients with iPD fulfilled Parkinson's UK Brain Bank criteria for the diagnosis of PD and patients with DLB had a diagnosis of probable DLB by 2017 Fourth consensus report of the DLB Consortium. All patients were studied in an on-medication condition to complete all study assessments. Before study inclusion and at year 3 follow-up all subjects underwent a restrictive screening protocol to exclude participants with relevant confounding factors potentially influencing clinical

Accepted Article

outcomes or retinal OCT measures. The screening protocol consisted in a comprehensive questionnaire on co-morbidities, an ophthalmological examination and a structural brain neuroimaging with 3 Tesla MRI. We excluded any subject with history of severe smoking (> 20 cigarettes/day) or heavy alcohol use (>4 drinks/day for men or >3 drinks/day for women), diagnosis of any type or grade of diabetes, uncontrolled or resistant elevated blood pressure, obesity (body mass index >30), history of consumption of drugs or medications known to induce retinal toxicity or cognitive impairment, chronic inflammatory systemic diseases (e.g. lupus erythematosus, sarcoid, Bechet disease), carotid or cerebral artery disease, moderate to severe deep white matter cerebral small vessel disease (Fazekas grade 2 or higher), history of brain trauma or other structural brain lesions or central nervous system diseases different from PD. Patients with well-controlled high blood pressure (hypertension) without complications were included in the study. We also excluded candidates with spherical equivalent refractive error above 4.00 diopters, more than 3.00 diopters of astigmatism or any other ocular condition potentially affecting OCT measures, as detailed in OSCAR-IB criteria²⁸. Lastly, to establish reference values for age-related changes in macular OCT measurements, we used a dataset of OCT images from 250 healthy volunteers. The study protocol was approved by the regional Basque Clinical Research Ethics Committee. All participants gave written informed consent prior to their participation in the study, in accordance with the tenets of the Declaration of Helsinki.

Demographical features and PD-related variables

Age at baseline and sex were recorded for all participants. Two neurologists experienced in the field of movement disorders recorded disease duration, Hoehn & Yahr scale score, Unified Parkinson Disease Rating Scale part III (motor examination) scores (UPDRS III) and Levodopa equivalent daily dose (LEDD).

Cognitive and visual outcomes assessment

General cognition was evaluated with Montreal Cognitive Assessment (MoCA)^{29, 30}. PD patients with severe cognitive deterioration at baseline visit (MoCA < 14) were excluded from the study. All visual function outcomes were obtained binocularly with best-corrected refraction. We registered high-contrast visual acuity (HCVA) and low-contrast visual acuity (LCVA) as the total number of letters correctly

Accepted Article

identified in, respectively, standard Early Treatment Diabetic Retinopathy Study (ETDRS) charts and Sloan 2.5% charts (Precision Vision, La Salle, IL) mounted in a retro-illuminated cabinet at 4 meters. Contrast sensitivity (CS) was measured with a Pelli-Robson chart at 1 meter under photopic conditions (280 lux) and the lowest contrast at which two letters in a triplet were correctly identified was recorded. In addition, we performed a detailed evaluation of visual cognition with tests including: the number of correct answers in Salthouse Perceptual Comparison Test, Symbol Digit Modalities Test, Picture Completion subtest of the Wechsler Adult Intelligence Scale (WAIS) IV, Benton Judgement of Line Orientation Test (H-form at baseline, V-form at follow-up), Number Location and Cube Analysis tests of the Visual Object and Space Perception (VOSP) battery, inverse of the time to complete Trail Making Test part-A, and the score in Clock Drawing Test (Rouleau scoring method).

OCT Acquisition, Segmentation, and Processing

Macular and peripapillary OCT images were acquired for each eye using Spectralis spectral-domain OCT (SD-OCT) (Heidelberg Engineering, Heidelberg, Germany) and thickness measures were calculated for peripapillary retinal nerve fiber layer (pRNFL) and for different combinations of layers and regions of the macula, as previously described²⁰ (see Figure 2). Briefly, macular scans consisted of 25 single horizontal axial scans covering a 20° x 20° area (512 A-scans per B-scan and 49 frames per B-scan). Peripapillary scans consisted of a 12° diameter ring scan manually centered on the optic nerve head (768 A scans per B scan, 100 frames per B-scan). All OCT images fulfilled OSCAR-IB quality control criteria²⁸. Baseline OCT images were selected as reference with the Follow-Up tool, which ensured identical positioning and scanning parameters at follow-up examinations.

Statistical analysis

Statistical analysis was done in R (version 3.6.1) and RStudio (version 1.2.1335). Group characteristics were compared using Fisher's exact test for categorical variables and Kruskal-Wallis test for quantitative variables. For describing longitudinal progression of OCT measurements, visual function, cognitive and motor parameters, multivariate linear mixed-effects regression models (LMM) (*lme4* package³¹) were used.

P-values were obtained with *lmerTest* package. Age and sex were used as fixed effects and a random intercept for subjects, separately in iPD patients and controls. To test for differences in retinal and clinical variables between iPD patients and controls, an interaction term between time and group was introduced. In patients, LMM was further adjusted for the following confounding variables: disease duration at study inclusion, UPDRS III score, LEDD, and diagnosis of hypertension. Lost to follow-up in patients was assumed not be at random since it was probably associated with study outcomes. Accordingly, to reduce estimate bias we also adjusted the LMM for the pattern of missing data (0=observation at two timepoints; 1=observation at baseline and missing data at follow-up).

For predicting clinical outcome worsening from OCT-derived and visual parameters, we first fitted linear models. Restricted cubic splines analysis with 5 knots revealed a non-linear relationship between baseline retinal variables and disease-related changes, which led us to calculate relative risks (RR). For the latter, outcomes were categorized as follows: we used a 5-point change in UPDRS III score as the clinically relevant change to consider motor worsening^{32,33}. The score of MoCA was considered to have declined if there was a reduction of 4 points or more, based on the upper limit of the lowest quartile of MoCA score changes across two time points in LBD patients. Predictor categorization was based on baseline measurements: we averaged baseline z-scores of low contrast visual acuity and visual cognition tests in LBD patients for classifying iPD patients into two groups using K-means clustering²⁰, and including DLB and E46K-SNCA within the classification as models. Also, iPD patients were categorized into retinal thickness tertiles. The tertile cutoffs were selected using as reference retinal thickness distribution of 250 controls aged 40 to 83 years. iPD patients below 25th percentile were assigned to the lowest thickness tertile (for parafoveal GCIPL: 72.1 to 89.7 μm ; for pRNFL: 83 to 92.5 μm), patients in the interquartile range were categorized as the intermediate tertile (parafoveal GCIPL: 89.7 to 98.9 μm ; pRNFL: 92.5 to 107 μm), and individuals above 75th percentile were allocated to the highest tertile (parafoveal GCIPL: 98.9 to 116 μm ; pRNFL: 107 to 125 μm). RR were adjusted for baseline age, disease duration, sex and LEDD with robust Poisson regression models. Logistic regression was used to test whether any baseline clinical variable was associated with motor or cognitive worsening.

RESULTS

Demographics and clinical features of study population at baseline

The demographics and clinical characteristics of study participants are detailed in Table 1. Briefly, DLB patients were significantly older (Bonferroni-corrected p -value < 0.05). Mean UPDRS III score was 27.6 in iPD, 10 points less than in DLB. Cognitive impairment was more severe for E46K-SNCA and DLB than for iPD, and MoCA score was significantly lower in iPD than in controls (Bonferroni-corrected p -value = 0.02). At study inclusion, 28.5% of iPD patients, 25% of E46K-SNCA and 62.5% DLB had well-controlled hypertension and the majority of iPD participants (83.7 %) were akinetic-rigid subtype.

Visual outcomes at baseline were worse in iPD patients compared to controls (Fig.1A), and, overall, visual impairment was more severe in E46K-SNCA and DLB patients (Table 1). According to baseline visual outcomes, iPD patients were phenotypically classified into 2 groups using K-means clustering. The first group, “moderate to severe visual dysfunction” group, included 16 iPD patients (32%), 7 DLB patients and 3 symptomatic E46K-SNCA carriers, whereas the second group, “mild visual dysfunction” group, included 34 iPD patients (68%), 1 DLB patient and 1 asymptomatic E46K-SNCA mutation carrier.

OCT measures at study inclusion showed that, in the central 3-mm of the macula, GCIPL was significantly thinner in DLB compared to iPD and controls, and inner nuclear layer (INL) thickness was significantly lower in E46K-SNCA carriers than in iPD. In fact, the difference was largest in the parafoveal area (*GCIPL*, DLB vs iPD $-9.6 \mu\text{m}$, DLB vs control $-10.7 \mu\text{m}$; *INL*, E46K-SNCA vs iPD $-4.25 \mu\text{m}$, E46K-SNCA vs controls $-3.27 \mu\text{m}$). Bonferroni-corrected pairwise comparisons were non-significant for the remaining thickness parameters of the macula and pRNFL.

At baseline, parafoveal thickness of GCIPL and INL in iPD were significantly correlated with MoCA score and UPDRS III score (Fig.3A), being correlation coefficients slightly higher for GCIPL than for INL. Cognitive and motor scores were not correlated in iPD patients, although the relationship was significant when AR-iPD subtype was separately analyzed ($r=-0.36$, $p=0.021$).

Progression of motor, cognitive and visual impairment after 3 years of follow-up

From the 50 LBD patients that completed follow-up visit, 17 patients (34%) (14 iPD, 1 DLB and 2 E46K-SNCA) suffered a clinically relevant motor progression (Δ UPDRS III \geq 5 points). Motor worsening was not associated with any baseline clinical variable, except for baseline UPDRS III score (OR: 0.897, $p=0.016$), whereby per one unit increase in the initial UPDRS III score the odds of having an increase of 5 points or more in UPDRS III at 3 years decreased by a factor of 0.90.

Regarding the progression of cognitive disability, iPD patients showed a significant decrease in the mean MoCA score (from 24.8 to 23.3, LMM $p=0.01$) while in controls it slightly increased from 26.8 to 27.6 (LMM, $p=0.360$). The decrease in the MoCA score was more pronounced for E46K-SNCA (from 19.0 to 15.5) and DLB (from 24.0 to 16.0) than for iPD. At follow-up, 8 iPD (19%), 4 DLB (100%) and 1 E46K-SNCA (25%) presented a worsening of 4 points or more in MoCA. Interestingly, cognitive worsening was not associated with initial MoCA score or any other demographic or disease-related clinical variable.

Although primary visual functions were clearly affected at baseline in iPD patients as compared to controls, the dynamics of the relative changes were similar, and we found only small differences over time (Fig.1B). Clinically significant worsening of high contrast visual acuity (loss of 5 or more letters, corresponding to one logMAR line of ETDRS chart) was observed in 2.5% of iPD patients, with no significant differences when compared to controls. The decrease in low contrast VA of 5 letters or more was present in a higher percentage of participants, but in a similar proportion between of iPD patients (20%) and controls (29.4%, $p=0.67$), and differences in annualized changes were not statistically significant (LMM, group x time, $p=0.781$). Intriguingly, the rate of low contrast VA deterioration was more prominent in E46K-SNCA and DLB groups (% change, -37.4 and -20.5, respectively) than in iPD or controls (Fig.3). In iPD patients, median contrast sensitivity decreased from 1.90 to 1.77 logCS at follow-up (LMM, $p<0.001$), whereas in controls the median of 2.10 logCS did not change, although the difference in the rate of contrast sensitivity change was not statistically significant (LMM, group x time, $p=0.06$). Regarding visual cognition tests, we failed to find within group significant changes at follow-up, except for Symbol Digit Modality Test in

controls (annualized estimate -1.5, $p=0.014$). However, we found a significant interaction effect of time and group for Benton Line Orientation Judgement (LMM, $p=0.04$), and Salthouse Perceptual Comparison Test (LMM, $p=0.03$) (Fig.1B).

Increased rate of GCIPL and peripapillary RNFL thinning in iPD patients

Using LMM analysis adjusted for age at baseline and sex, we detected a distinct rate of macular GCIPL atrophy between iPD patients and controls (Fig.2). In the control group, the annualized estimates of GCIPL thickness were $-0.33 \mu\text{m}$ in the 6-mm disc, $-0.19 \mu\text{m}$ in the central 3-mm disc and $+0.07 \mu\text{m}$ in central 1-mm disc. Additionally, when the annualized GCIPL estimates were calculated in controls for rings around the fovea, $-0.23 \mu\text{m}$ decrease was found in 1- to 3- mm (parafoveal) ring, and $-0.37 \mu\text{m}$ in the 3- to 6-mm perifoveal ring (Table 2). In iPD patients, the annual rate of atrophy was largest in the parafoveal ring ($-0.67 \mu\text{m}$), which was two times greater than in controls and statistically significant (LMM, group x time, $p=0.007$). Similarly, the overall thickness loss in 3-mm disc ($-0.63 \mu\text{m}$) was also significant and significantly higher than in controls (LMM, group x time, $p=0.005$), as well as within the central 1-mm disc ($-0.24 \mu\text{m}$, LMM group x time, $p=0.045$). However, the rate of thinning in the 6-mm disc ($-0.51 \mu\text{m}$) and 3- to 6- mm perifoveal ring ($-0.47 \mu\text{m}$) was not significantly different in iPD patients compared to controls. These estimates slightly increased after adjusting for age and disease duration at baseline, sex, UPDRS III score, LEDD, hypertension and missing data pattern (Table 2). When other macular layers were evaluated using LMM, we only observed statistically significant changes for outer plexiform-Henle fiber-outer nuclear layer complex (OPL-HF-ONL) complex in iPD patients, with a thinning ranging from -0.39 to $-0.25 \mu\text{m}$, but this thinning rate was not statistically different from that observed in controls. The average pRNFL thickness also decreased significantly over time in iPD patients ($-0.55 \mu\text{m}/\text{year}$, $p<0.001$) but not in controls ($-0.15 \mu\text{m}/\text{year}$, $p=0.192$) (LMM group x time, $p=0.015$) (Table 2).

Prediction of disease worsening from retinal OCT and visual function parameters

Our results showed that iPD patients in the lowest parafoveal GCIPL thickness tertile at baseline had increased adjusted relative risk (RR) of cognitive worsening compared with those in higher tertiles (RR

3.49, 95% CI 1.10 – 11.11, p=0.03). On the other hand, the risk of motor worsening of iPD patients based on baseline parafoveal GCIPL thickness was not significant (RR 0.63, 95% CI 0.57 – 6.18, p=0.566). Similarly, the RR of cognitive decline between patients in the lowest pRNFL tertile compared to patients in the intermediate and highest pRNFL tertiles was significant (RR 3.28, 95% CI 1.03 – 10.45, p=0.045), but not for motor deterioration (RR 1.91, 95% CI 0.75 – 4.90, p=0.193). When patients were classified according to their visual outcomes at baseline, the risk of general cognition worsening was almost five times greater for patients with visual dysfunction (RR 4.69, 95% CI 1.34 – 16.5, p=0.01), even after adjusting for confounders (RR 4.79, 95% CI 0.91 – 21.18, p=0.06). Conversely, the risk of motor deterioration was not different for patients with and without initial visual impairment (adjusted RR 1.15, 95% CI 0.36 – 3.61, p=0.242).

DISCUSSION

To the best of our knowledge, this is the first prospective longitudinal study to investigate the rate of GCIPL and pRNFL thinning over time in iPD patients using SD-OCT, and the first to show that GCIPL thickness measured by OCT at a single timepoint can be used as a marker of subsequent worsening of general cognition.

Age-related reduction rate of GCIPL thickness in healthy population has been measured in previous OCT studies, with estimated annual thinning up to 0.25 μm in cross-sectional studies and 0.19 μm to 0.32 μm in longitudinal studies^{34,35}, which is in line with the annual decrease of 0.33 μm that we found for the control group in our study. However, the progression of disease-related retinal thinning in iPD has not been extensively explored. Previous studies investigating longitudinal retinal changes in PD have only evaluated total macular volume or average pRNFL thickness²⁵⁻²⁷. In a prospective 5-year follow-up study, Satue et al.²⁶ reported for the first time that macular thinning in PD patients was greater than in controls, finding the largest differences in inner nasal (-8.21 μm), outer inferior (-7.85 μm) and inner temporal (-6.87 μm) macular sectors. These authors also reported that, compared to controls, pRNFL thickness reduction was significantly higher in temporal and superotemporal sectors (3 to 4 μm thinning). Later, Ma et al.²⁷ found

in a study of 22 PD patients that macular thickness decreased 7 μm and pRNFL 6 μm after 2.5 years of follow-up. A more recent study evaluating 19 early-stage PD patients found a mean decrease in macular thickness of 7.4 μm without significant changes in pRNFL thickness after an average follow-up of 19 ± 8.5 months²⁵. In our study, pRNFL thickness reduction was almost 4 times greater in patients, with a comparable annual thinning rate to that found by Satue et al.²⁶. More importantly, according to our findings, the progression of GCIPL atrophy in the macula was three times greater in iPD patients than in controls. Unfortunately, the lack of longitudinal OCT studies evaluating GCIPL thinning over time in PD, renders it difficult to compare our results.

Our findings revealed that iPD patients with lower initial GCIPL and pRNFL thicknesses presented an increased risk of cognitive decline at 3 years. Similarly, iPD patients with visual dysfunction at baseline had 4-times the risk of global cognition deterioration at follow-up. Furthermore, in our study, GCIPL and pRNFL measurements were not associated with the progression of motor features. No significant differences were observed in terms of age, sex, LEDD, disease duration and general cognition in patients with and without motor progression, but lower UPDRS III score at baseline was associated with motor progression. The pathophysiological explanation for the observed relationship between the progression of cognitive decline and retinal atrophy and the lack of association of the latter with the progression of motor symptoms is intriguing. First, it is important to bear in mind that visual stimuli are the main input for most of the standard neuropsychological tests and that the retina is the first processing station of visual information in the central nervous system. Basic computations for the analysis and interpretation of images, like edge detection, are accomplished in the retina, where immunohistological studies in PD have detected neuronal loss, synaptic and dendritic abnormalities and deposits of phosphorylated alpha-synuclein, especially in ganglion cells²¹. While abnormalities in perception and processing of visual information in PD might be in part related to the injury of cortical and subcortical areas of the brain³⁶⁻³⁸, the involvement of the retina in visual cognition abnormalities of PD patients is firmly supported by several *in-vivo* electrophysiological and OCT studies³⁹. Our findings underpinning that visual dysfunction and macular GCIPL and pRNFL atrophy can independently predict the progression of cognitive disability in iPD are

supported by the recent publication by Leyland et al.¹⁸. Moreover, visual loss has an impact on physical activity, mental stimulation and social interactions - factors reported to reduce the progression of cognitive impairment and the risk of dementia⁴⁰. Therefore, all the aforementioned aspects may contribute to the effect of retinal injury and associated visual impairment on future risk of dementia, as observed in elderly population^{41,42}. Finally, our findings showing a lack of association between motor worsening and macular GCIPL atrophy may suggest different pathophysiological mechanisms underlying neurodegeneration of the retina and brain structures involved in motor manifestations. To date only one neuroimaging study has evaluated *in-vivo* the relation between retinal thickness and the integrity of brain regions involved in motor manifestations of PD, finding an association between inner retinal atrophy and lower dopamine transporter (DAT) uptake in substantia nigra⁴³. However, the majority of previous OCT studies in PD failed to demonstrate statistically significant results or yielded contradictory findings regarding the link between retinal atrophy and motor disability or disease duration²². Given that macular GCIPL atrophy has been reported in *de novo* PD patients²³ and in prodromal phases of LBD²⁴ and the lack of its correlation with disease duration or motor manifestations, it may suggest that retinal injury is an early phenomenon of iPD. Nonetheless, the mechanisms mediating the initiation and progression of retinal thinning in iPD are unknown. Ortuño-Lizaran et al.⁴⁴ identified phosphorylated alpha-synuclein reactive cells in the retina of 9 postmortem PD patients and 4 patients with incidental LBD. More recently, Shi et al.⁴⁵ observed that retinal capillary complexity was decreased in the 2.5 mm annular zone that approximately coincides with parafoveal region in which we found the largest retinal atrophy. In line with this, Kwamong et al.⁴⁶ found a correlation between the impairment in the microvasculature in that area and GCIPL thinning. However, the precise contribution of the microvasculature and alpha-synuclein as a causal factor for inner retinal thinning remains challenging, and probably several non-identified factors contribute. Regardless of the cause, our study showed that GCIPL thickness, mainly in the parafoveal region, and pRNFL thickness in iPD patients decreased at a faster rate than in the controls, and patients with lower baseline retinal measures were at higher risk of suffering cognitive decline.

Our study has some limitations. First, the confidence intervals of the estimated risk of our analyses are wide, probably as the result of the sample size. Secondly, clinically significant changes for UPDRS III have been reported in the literature, and 5-point cut-off value is valid in clinical practice for patients with HY scores I to III, as in our sample^{32, 33}. However, the clinically significant change for MoCA score in iPD has not been established. We used a 4-point cut-off value based on the distribution of MoCA changes in LBD patients, but this value may need to be confirmed in future studies. Another potential limitation is that we did not consider the influence of non-dopaminergic medications in cognitive and visual function. Also, loss to follow-up in patients was assumed to be not at random, which might have biased the estimates of risk ratios. Therefore, our data should be interpreted with caution. Despite these limitations, this study had many strengths. Due to the prospective study design, we were able to observe changes in GCIPL and pRNFL thickness of iPD patients at 3 years. Moreover, mixed-models were used for controlling for within-patient correlations and missing data pattern was introduced in the models - which is more robust for longitudinal data analysis than previously used statistical analyses. Finally, predictions of motor and cognitive impairment from baseline OCT measures have not been previously contemplated in iPD and robust Poisson models were used to provide unbiased estimates of risk ratios.

In conclusion, this work represents the first prospective longitudinal OCT study investigating the rate of retinal thinning over time in iPD patients and its relationship with motor and cognitive outcomes. As the main findings, we showed that after 3 years of follow up the progression of macular GCIPL and pRNFL atrophy was three to four times greater in iPD patients than in controls and that retinal thickness measured by OCT at a single timepoint could be used as a potential markers of subsequent worsening of general cognition in iPD. Future studies with larger sample sizes and more follow-up time points will be needed to validate the suitability of macular GCIPL and pRNFL thickness measurement with OCT for monitoring neurodegeneration and as an imaging biomarker of cognitive decline in iPD.

ACKNOWLEDGMENT

The authors want to thank all the patients and participants involved in the study. This study was partially co-funded by Michael J. Fox Foundation [RRIA 2014 (Rapid Response Innovation Awards) Program (Grant ID: 10189)], by the Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, "A way to make Europe"/"Investing in your future") through the projects "PI14/00679" and "PI16/00005", and the Juan Rodes grant "JR15/00008" (IG), and by the Department of Health of the Basque Government through the project "2016111009" and "2020333033".

AUTHOR CONTRIBUTIONS

AMG, JCG and IG contributed to the conception and design of the study. AMG, RP, MG, BA, MA, MCA, TF, BT and OLJ contributed to the acquisition of data. AMG, UA, MB and JC contributed to data analysis. AMG and IG contributed to drafting the text and preparing the figures.

POTENTIAL CONFLICTS OF INTEREST

Nothing to report.

REFERENCES

1. Lanskey JH, McColgan P, Schrag AE, et al. Can neuroimaging predict dementia in Parkinson's disease? *Brain*. 2018 Sep 1;141(9):2545-60.
2. Espay AJ, Kalia LV, Gan-Or Z, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? *Neurology*. 2020 Mar 17;94(11):481-94.
3. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Annals of neurology*. 2004 Feb;55(2):164-73.
4. Hamilton JM, Salmon DP, Galasko D, et al. Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. *Neuropsychology*. 2008 Nov;22(6):729-37.
5. Somme JH, Gomez-Esteban JC, Molano A, Tijero B, Lezcano E, Zarranz JJ. Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1). *Journal of the neurological sciences*. 2011 Nov 15;310(1-2):86-9.
6. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. *Brain : a journal of neurology*. 1987 Dec;110 (Pt 6):1675-98.
7. Boller F, Passafiume D, Keefe NC, Rogers K, Morrow L, Kim Y. Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. *Archives of neurology*. 1984 May;41(5):485-90.
8. Crucian GP, Okun MS. Visual-spatial ability in Parkinson's disease. *Frontiers in bioscience : a journal and virtual library*. 2003 Sep 1;8:s992-7.
9. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. *Clinical neuropharmacology*. 1998 Sep-Oct;21(5):289-95.
10. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. *Archives of neurology*. 2002 Aug;59(8):1249-52.
11. Hutton JT, Morris JL, Elias JW, Varma R, Poston JN. Spatial contrast sensitivity is reduced in bilateral Parkinson's disease. *Neurology*. 1991 Aug;41(8):1200-2.
12. Langheinrich T, Tebartz van Elst L, Lagreze WA, Bach M, Lucking CH, Greenlee MW. Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. 2000 Jan;111(1):66-74.
13. Lin TP, Rigby H, Adler JS, et al. Abnormal visual contrast acuity in Parkinson's disease. *Journal of Parkinson's disease*. 2015;5(1):125-30.
14. Mestre D, Blin O, Serratrice G, Pailhous J. Spatiotemporal contrast sensitivity differs in normal aging and Parkinson's disease. *Neurology*. 1990 Nov;40(11):1710-4.
15. Ming W, Palidis DJ, Spering M, McKeown MJ. Visual Contrast Sensitivity in Early-Stage Parkinson's Disease. *Investigative ophthalmology & visual science*. 2016 Oct 1;57(13):5696-704.
16. Regan D, Neima D. Visual fatigue and visual evoked potentials in multiple sclerosis, glaucoma, ocular hypertension and Parkinson's disease. *Journal of neurology, neurosurgery, and psychiatry*. 1984 Jul;47(7):673-8.
17. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. *Brain*. 2007 Jul;130(Pt 7):1787-98.
18. Leyland LA, Bremner FD, Mahmood R, et al. Visual tests predict dementia risk in Parkinson disease. *Neurology Clinical practice*. 2020 Feb;10(1):29-39.
19. Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. *Neurology*. 2014 Sep 30;83(14):1253-60.
20. Murueta-Goyena A, Del Pino R, Reyero P, et al. Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases. *Movement disorders : official journal of the Movement Disorder Society*. 2019 May 28.
21. Veys L, Vandenberghe M, Ortuno-Lizaran I, et al. Retinal alpha-synuclein deposits in Parkinson's disease patients and animal models. *Acta Neuropathol*. 2019 Mar;137(3):379-95.

22. Chrysou A, Jansonius NM, van Laar T. Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies. *Parkinsonism Relat Disord*. 2019 Jul;64:40-9.
23. Sung MS, Choi SM, Kim J, et al. Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson's disease. *Sci Rep*. 2019 Aug 14;9(1):11832.
24. Lee JY, Ahn J, Oh S, et al. Retina thickness as a marker of neurodegeneration in prodromal lewy body disease. *Movement disorders : official journal of the Movement Disorder Society*. 2020 Feb;35(2):349-54.
25. Hasanov S, Demirkilinc Biler E, Acarer A, Akkin C, Colakoglu Z, Uretmen O. Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson's disease. *International ophthalmology*. 2019 Jun;39(6):1255-62.
26. Satue M, Rodrigo MJ, Obis J, et al. Evaluation of Progressive Visual Dysfunction and Retinal Degeneration in Patients With Parkinson's Disease. *Investigative ophthalmology & visual science*. 2017 Feb 1;58(2):1151-7.
27. Ma LJ, Xu LL, Mao CJ, et al. Progressive Changes in the Retinal Structure of Patients with Parkinson's Disease. *Journal of Parkinson's disease*. 2018;8(1):85-92.
28. Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. *PloS one*. 2012;7(4):e34823.
29. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*. 2005 Apr;53(4):695-9.
30. Ojeda N, Del Pino R, Ibarretxe-Bilbao N, Schretlen DJ, Pena J. [Montreal Cognitive Assessment Test: normalization and standardization for Spanish population]. *Revista de neurologia*. 2016 Dec 1;63(11):488-96.
31. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015. 2015-10-07;67(1):48.
32. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. *Movement disorders : official journal of the Movement Disorder Society*. 2006 Aug;21(8):1200-7.
33. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. *Archives of neurology*. 2010 Jan;67(1):64-70.
34. Leung CKS, Ye C, Weinreb RN, Yu M, Lai G, Lam DS. Impact of age-related change of retinal nerve fiber layer and macular thicknesses on evaluation of glaucoma progression. *Ophthalmology*. 2013 Dec;120(12):2485-92.
35. Lee WH, Lee MW, Lim HB, Kim KM, Shin YI, Kim JY. Longitudinal changes in the thickness of the ganglion cell-inner plexiform layer in patients with hypertension: a 4-year prospective observational study. *Acta ophthalmologica*. 2019 Oct 28.
36. Weil RS, Winston JS, Leyland LA, et al. Neural correlates of early cognitive dysfunction in Parkinson's disease. *Annals of clinical and translational neurology*. 2019 May;6(5):902-12.
37. Moro E, Bellot E, Meoni S, et al. Visual Dysfunction of the Superior Colliculus in De Novo Parkinsonian Patients. *Ann Neurol*. 2020 Apr;87(4):533-46.
38. Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. *Brain*. 2014 Mar;137(Pt 3):849-59.
39. Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson's disease. *Brain : a journal of neurology*. 2016 Nov 1;139(11):2827-43.
40. Ruthirakuhan M, Luedke AC, Tam A, Goel A, Kurji A, Garcia A. Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review. *J Aging Res*. 2012;2012:384875.
41. Tran EM, Stefanick ML, Henderson VW, et al. Association of Visual Impairment With Risk of Incident Dementia in a Women's Health Initiative Population. *JAMA Ophthalmol*. 2020 Apr 16.
42. Nael V, Peres K, Dartigues JF, et al. Vision loss and 12-year risk of dementia in older adults: the 3C cohort study. *Eur J Epidemiol*. 2019 Feb;34(2):141-52.

43. Ahn J, Lee JY, Kim TW, et al. Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. *Neurology*. 2018 Sep 11;91(11):e1003-e12.
44. Ortuno-Lizaran I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N. Phosphorylated alpha-synuclein in the retina is a biomarker of Parkinson's disease pathology severity. *Movement disorders : official journal of the Movement Disorder Society*. 2018 May 8.
45. Shi C, Chen Y, Kwapong WR, et al. CHARACTERIZATION BY FRACTAL DIMENSION ANALYSIS OF THE RETINAL CAPILLARY NETWORK IN PARKINSON DISEASE. *Retina (Philadelphia, Pa)*. 2019 Aug 29.
46. Kwapong WR, Ye H, Peng C, et al. Retinal Microvascular Impairment in the Early Stages of Parkinson's Disease. *Investigative ophthalmology & visual science*. 2018 Aug 1;59(10):4115-22.



FIGURE LEGENDS



Figure 1. Visual outcomes. (A) Differences in baseline visual outcomes between controls and iPD patients. Significant differences are indicated with an asterisk (Wilcoxon Rank Sum Test, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). (B) Longitudinal changes in visual outcomes. Relative changes (percentage) of visual outcomes were calculated as $[(\text{follow-up visual score} - \text{baseline visual score}) / \text{baseline visual score}] * 100$. # $p\text{-value} < 0.05$ for the interaction term between group and time in linear mixed models. Note that the results of $n=50$ iPD patients and $n=29$ controls are represented in (A) and the results of $n=42$ iPD patients and $n=17$ controls in (B). *Abbreviations:* BLOJ, Benton Line Orientation Judgment; CS, contrast sensitivity; CDT, Clock Drawing Test, reproduction, corrected with Rouleau method; HCVA, high-contrast visual acuity (number of correct letters); LCVA, low-contrast visual acuity (number of correct letters); SMDT, Symbol Digit Modality Test; SPCT, Salthouse Perceptual Comparison Test; TMT, part-A (s), time to complete Trail Making Test, part-A; VOSP, CA, cube analysis subitem of VOSP; VOSP, NL, number location subitem of VOSP; WAIS, Figure completion part of WAIS-IV.



Figure 2. Progression of retinal atrophy in peripapillary RNFL, and in 5 layer-complexes of the macula divided in 1-mm, 1- to 3-mm and 3- to 6-mm areas. The 1- to 3-mm area corresponds to the parafoveal area of the macula. Estimated changes of macular and peripapillary thickness between baseline and year 3 follow-up, adjusted for age and sex, are displayed and negative values represent retinal thinning over time. *Abbreviations:* ELM-BM, retinal complex including external limiting membrane, ellipsoid band, retinal pigment epithelium and Bruch membrane; GCIPL, ganglion cell-inner plexiform complex; INL, inner nuclear layer of the retina; LBD, Lewy body diseases; mRNFL, macular nerve fiber layer; OPL-HF-ONL, outer plexiform-Henle fiber-outer nuclear layer complex; pRNFL, peripapillary retinal nerve fiber layer.

Figure 3. (A) Scatterplots represent the relationship between GCIPL thickness in the parafoveal area (1- to 3-mm) and MoCA and UPDRS III scores at baseline. (B) Progression of cognitive and motor manifestations. Parameter estimates from linear mixed-effect models were converted to and plotted as condition means and SE. iPD patients were divided into subgroups according to baseline thickness in the parafoveal area (1- to 3-mm ring) of GCIPL in the macula, baseline pRNFL thickness, and baseline visual



outcomes. Retinal thicknesses of iPD patients were divided into tertiles according to the reference population, and visual impairment was determined using K-means clustering (see methods). 11 iPD patients from the lowest retinal thickness tertile and 31 iPD patients from the intermediate and highest tertiles completed follow-up visit. 31 patients that were classified as mild visual dysfunction and 11 as moderate to severe visual dysfunction completed 3-year visit. *Abbreviations:* GCIPL, ganglion cell-inner plexiform complex; MoCA, Montreal Cognitive Assessment; pRNFL, peripapillary nerve fiber layer; r , Pearson correlation coefficient; UPDRS III, Unified Parkinson's Disease Rating Scale, motor examination.

A


A






This article is protected by copyright. All rights reserved.





Thickness change (μm)



This article is protected by copyright. All rights reserved.

A**B**

A**B**